Stock Track | SKB BIO Soars 5.22% Intraday on Positive Phase III Trial Results and Regulatory Approval

Stock Track

May 21

SKB BIO's stock surged 5.22% during intraday trading on Thursday, driven by positive clinical developments and regulatory progress.

The rally was fueled by Merck's announcement that sacituzumab tirumotecan (sac-TMT), a TROP2 antibody-drug conjugate licensed from SKB BIO, successfully met both overall survival and progression-free survival co-primary endpoints in the global Phase III TroFuse-005 trial for advanced or recurrent endometrial cancer. This marks the first Phase III ADC trial to demonstrate dual improvement in this indication, positioning sac-TMT as a potential backbone therapy.

Additionally, the company's PD-1×VEGF bispecific antibody SKB118 received Investigational New Drug (IND) approval from China's National Medical Products Administration for advanced solid tumors, further strengthening its pipeline momentum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1133296679"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133296679\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133296679?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133296679","market":"us","top_or_hot":-1,"title":"Stock Track | SKB BIO Soars 5.22% Intraday on Positive Phase III Trial Results and Regulatory Approval","media":"Stock Track","content":"<p>SKB BIO's stock surged 5.22% during intraday trading on Thursday, driven by positive clinical developments and regulatory progress.</p><p>The rally was fueled by Merck's announcement that sacituzumab tirumotecan (sac-TMT), a TROP2 antibody-drug conjugate licensed from SKB BIO, successfully met both overall survival and progression-free survival co-primary endpoints in the global Phase III TroFuse-005 trial for advanced or recurrent endometrial cancer. This marks the first Phase III ADC trial to demonstrate dual improvement in this indication, positioning sac-TMT as a potential backbone therapy.</p><p>Additionally, the company's PD-1×VEGF bispecific antibody SKB118 received Investigational New Drug (IND) approval from China's National Medical Products Administration for advanced solid tumors, further strengthening its pipeline momentum.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SKB BIO Soars 5.22% Intraday on Positive Phase III Trial Results and Regulatory Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SKB BIO Soars 5.22% Intraday on Positive Phase III Trial Results and Regulatory Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-21 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SKB BIO's stock surged 5.22% during intraday trading on Thursday, driven by positive clinical developments and regulatory progress.</p><p>The rally was fueled by Merck's announcement that sacituzumab tirumotecan (sac-TMT), a TROP2 antibody-drug conjugate licensed from SKB BIO, successfully met both overall survival and progression-free survival co-primary endpoints in the global Phase III TroFuse-005 trial for advanced or recurrent endometrial cancer. This marks the first Phase III ADC trial to demonstrate dual improvement in this indication, positioning sac-TMT as a potential backbone therapy.</p><p>Additionally, the company's PD-1×VEGF bispecific antibody SKB118 received Investigational New Drug (IND) approval from China's National Medical Products Administration for advanced solid tumors, further strengthening its pipeline momentum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1133296679","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133296679","pubTimestamp":1779328497,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SKB BIO's stock surged 5.22% during intraday trading on Thursday, driven by positive clinical developments and regulatory progress.The rally was fueled by Merck's announcement that sacituzumab...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"个股追踪|SKB生物盘中大涨5.22%因III期试验结果积极及监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"SKB BIO's stock surged 5.22% during intraday trading on Thursday, driven by positive clinical developments and regulatory progress.The rally was fueled by Merck's announcement that sacituzumab tirumotecan (sac-TMT), a TROP2 antibody-drug conjugate licensed from SKB BIO, successfully met both overall survival and progression-free survival co-primary endpoints in the global Phase III TroFuse-005 trial for advanced or recurrent endometrial cancer. This marks the first Phase III ADC trial to demonstrate dual improvement in this indication, positioning sac-TMT as a potential backbone therapy.Additionally, the company's PD-1×VEGF bispecific antibody SKB118 received Investigational New Drug (IND) approval from China's National Medical Products Administration for advanced solid tumors, further strengthening its pipeline momentum.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}